View All Articles
Prostate cancer is a curable disease for many patients. In fact, for some men, it requires no treatment at all – but we at the Brady want to make sure we correctly and safely identify those men. For men who do need treatment, we want to address their cancer with few to no side effects.
In a recent study, Matoso and colleagues assessed the sensitivity of blue light cystoscopy, and compared the results with the final pathology diagnoses. They found blue light cystoscopy allows them to detect CIS that would have been under-diagnosed with the conventional white light cystoscopy.
“We saw a reduction in opioid prescribing by nearly 47 percent, a reduction in opioid use by nearly 27 percent, and increased disposal of leftover opioids by nearly 14 percent.”
They don’t happen often, but Brady urologists would like to prevent them altogether: blood clots in the legs or lungs after radical prostatectomy.
Carter, retiring as the Bernard L. Schwartz Distinguished Professor of Urologic Oncology, reflects on his 32 years at the Brady.
Prostate-specific RNA in the urine may lead to a new test for clinically significant prostate cancer, and may show which men have more aggressive disease.
New hope for patients with a rare, extremely aggressive form of bladder cancer: “very encouraging responses” to an intense, triple-drug, neoadjuvant chemotherapy approach, followed by cystectomy (surgical removal of the bladder).
When it comes to chemotherapy for urothelial cancer, does location matter? Hopkins scientists are working to find out.
Scientist Woonyoung Choi, Ph.D., who led genomic studies that identified the basal and luminal molecular subtypes of bladder cancer, has discovered that the immune system plays a powerful role in how patients respond to chemotherapy.
Maintenance dosing of intravesical combination chemotherapy “leads to more durable responses than induction treatment alone.”